Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [3][4] - The company will present at The Citizens Life Sciences Conference on May 8, 2025, with CEO Gene Mack participating in one-on-one meetings [1] - Gain's lead drug candidate, GT-02287, is currently in a Phase 1b clinical trial for treating Parkinson's disease and has potential applications in other neurodegenerative diseases [3][4] Company Overview - Gain Therapeutics specializes in discovering and developing allosteric therapies, with a unique approach to creating small molecule modulators that can alter protein function [3][4] - The company utilizes its advanced Magellan™ platform to accelerate drug discovery for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4] Clinical Development - GT-02287 is being evaluated for Parkinson's disease treatment, with further potential in conditions like Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [3] - Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [3]